查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
心臟生物標記:各種技術和全球市場
市場調查報告書
商品編碼
1210811

心臟生物標記:各種技術和全球市場

Cardiac Biomarkers: Technologies and Global Markets
出版日期: | 出版商: BCC Research | 英文 287 Pages | 訂單完成後即時交付

價格

全球心臟生物標記的市場規模，從2022年的134億美元，預計2027年成長到238億美元，從2022年到2027年的年複合成長率為12.2％。

肌鈣蛋白的部門，從2022年的39億美元，預計2027年成長到72億美元，從2022年到2027年的年複合成長率預計為13.1％。還有BNP、NT-proBNP、MR-proANP的部門，從2022年的31億美元，預計2027年成長到55億美元，年複合成長率預計為12.4％。

本報告提供全球心臟生物標記的市場調查，心血管疾病及心臟生物標記概要，主要心臟生物標記的檢討，市場規模的變化、預測，各種區分、各地區的詳細分析，影響因素的分析，法律制度，專利趨勢，競爭環境，主要企業簡介等彙整資訊。

目錄

第1章 簡介

第2章 摘要、亮點

第3章 心血管疾病其伴隨的負擔

  • 心血管疾病概要
    • 冠狀動脈疾病
  • 動脈粥狀硬化性心血管疾病
  • 心絞痛
  • 急性心肌梗塞 (AMI)
  • 疾病管理
  • 醫療管理
  • 生活方式的變化
  • 飲食的變更
  • 戒煙
  • 醫藥品
  • 抗凝固藥和抗血小板藥
  • 脂質低墮胎藥
  • 降壓藥
  • 硝化甘油製劑
  • 外科的介入
    • 冠狀動脈繞道手術
    • 經心肌血液循環重組術
    • 經皮冠狀動脈介入治療
  • 全球心血管病患的負擔

第4章 心臟生物標記:簡介

  • 生物標記的各種類型
  • 心臟衰竭的預防，評估，管理上生物標記所扮演的角色
  • 生物標記的發現與檢驗
  • 生物標記的發現的組學技術
  • 心臟生物標記開發時候的考慮事項
  • 異常的生物標記價值定義
  • 生物標記準確度的ROC曲線分析

第5章 主要心臟生物標記的檢討

  • 心臟生物標記的黃金標準
  • 肌鈣蛋白複合體
  • Pro-BNP、NT-proBNP
  • 肌酸激酶試驗
  • 肌紅蛋白 (Mb)
  • C反應性蛋白質
  • 其他
    • 和肽素
    • D-二聚體
    • 半乳糖凝集素-3
    • 脂肪酸結合蛋白質
    • ST2
  • 新的心臟生物標記
    • 膽鹼
    • 缺血修飾白蛋白
    • 髓過氧化物酶
    • S100-β
  • 心臟生物標記檢測的最近技術進步的主要發展
    • 促進因素
    • 障礙
    • 驗證的障礙
    • 顯著的技術進步

第6章 全球心臟生物標記市場

  • 全球市場:各生物標記類型
    • 地區概要
  • 北美
  • 歐洲
  • 亞太地區
  • 其他地區

第7章 COVID-19影響

第8章 心臟生物標記相關法規必要條件

第9章 心臟生物標記的專利檢討、新的開發

第10章 競爭情形

  • 企業佔有率分析
  • 最近的新聞

第11章 企業簡介

  • ABBOTT LABORATORIES
  • ACS BIOMARKER BV
  • BECKMAN COULTER
  • BG MEDICINE INC.
  • BIOMERIEUX S.A.
  • BIO-RAD LABORATORIES, INC.
  • CARDIOGENICS
  • CREATIVE DIAGNOSTICS
  • CRITICAL DIAGNOSTICS
  • LIFE DIAGNOSTICS INC.
  • LIFESIGN
  • LSI MEDIENCE CORP.
  • MERIDIAN LIFE SCIENCE INC.
  • METANOMICS HEALTH GMBH
  • ORTHO-CLINICAL DIAGNOSTICS INC.
  • PERKINELMER INC.
  • PTS DIAGNOSTICS
  • QUIDEL CORP.
  • RADIOMETER MEDICAL APS
  • RANDOX LABORATORIES LTD.
  • RESPONSE BIOMEDICAL CORP.
  • ROCHE DIAGNOSTICS
  • SANYO CHEMICAL INDUSTRIES LTD.
  • SIEMENS AG
  • SINGULEX INC.
  • SPECTRAL MEDICAL INC.
  • THERMO FISHER SCIENTIFIC, INC.
  • TOSOH BIOSCIENCE INC.
  • TRINITY BIOTECH PLC

第12章 附錄A:企業聯繫資訊

第13章 附錄B:政府法規機關、專門機關

第14章 附錄C:縮寫

Product Code: BIO128D

Highlights:

The global market for cardiac biomarkers is estimated to increase from $13.4 billion in 2022 to reach $23.8 billion by 2027, at a compound annual growth rate (CAGR) of 12.2% from 2022 through 2027.

The troponin segment of the global cardiac biomarkers market is estimated to increase from $3.9 billion in 2022 to reach $7.2 billion by 2027, at a CAGR of 13.1% from 2022 through 2027.

The BNP, NT-proBNP and MR-proANP segment of the global cardiac biomarkers market is estimated to increase from $3.1 billion in 2022 to reach $5.5 billion by 2027, at a CAGR of 12.4% from 2022 through 2027.

Report Scope:

The scope of this report is -

  • Identify viable technology drivers through a comprehensive look at various platform technologies for cardiac marker segments of the diagnostic testing market.
  • Obtain a complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing and theragnostic, while also gaining an appreciation these elements from their basic principles to their applications.
  • Discover feasible market opportunities via the identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases.
  • Focus on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth.
  • Present market figures for the current value of the cardiac biomarkers market, projections and growth rates. These are developed from the most recently available information from the global diagnostics industry.

By purchasing this study, the reader will gain -

  • An improved understanding of the current state and future of the most exciting cardiac biomarker market segments.
  • The latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline.
  • Knowledge of the cardiac diagnostic testing market as an area of growth, research and investment.

This analysis covers the following categories of the cardiac biomarker segments -

  • Acute Myocardial Infarction (AMI).
  • Heart failure.
  • Brain natriuretic peptide (BNP).
  • Myoglobin.
  • Homocysteine (Hcy).
  • C-reactive protein (CRP).
  • Pulmonary embolism (PE) D-dimer test.
  • Low-density lipoproteins (LDL) and high-density lipoproteins (HDL).
  • Stroke.
  • Creatine kinase-myocardial band (CK-MB) and cardiac enzymes.
  • Albumin.
  • Cardiac markers are used in clinical decisions.
  • Cardiac markers in renal failure.
  • Troponins in non-ischemic heart disease.
  • Cardiac panels.
  • POC cardiac markers.

Analyses include charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research on various illnesses provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report. In addition, the study -

  • Assesses cardiac marker diagnostic testing market drivers and bottlenecks from the perspective of the medical and scientific communities.
  • Discusses the potential benefits of the cardiac marker diagnostic testing market for various sectors of the medical and scientific community.
  • Establishes the current total market size and future growth of the cardiac marker diagnostic testing market and analyzes the current size and growth of individual segments.
  • Provides current and forecasted market shares by company.
  • Discusses profit and business opportunities by diagnostic testing segment.
  • Provides strategic recommendations for near-term business opportunities.
  • Assesses current commercial uses of the cardiac biomarker market.

Report Includes:

  • 66 data tables and 36 additional tables
  • An up-to-date overview and analysis of the global markets for cardiac biomarkers technologies
  • Analyses of the global market trends, with historic revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Estimation of the actual market size and revenue forecast for cardiac biomarkers market in USD million terms, and corresponding market share analysis based on the type of biomarker, instrument category, and region
  • Identification of the viable technology drivers and barriers through a holistic review of various platform technologies in cardiac biomarker measurement and their notable advancements
  • Complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing, and theranostics, while also appreciating these elements from their basic principles to their applications
  • Discussion of feasible market opportunities via identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases
  • Emphasis on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth
  • Latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline with SWOT analyses
  • Review of the patents and patent applications on cardiac biomarkers and deep dive of recent global and region-specific patent publications related to cardiac biomarkers
  • Insight into the company competitive landscape and company value share analysis for the leading suppliers of cardiac biomarkers
  • Profile descriptions of the major global players, including Abbott Laboratories, Beckman Coulter (subsidiary of Danaher Corp.), bioMerieux S.A., PerkinElmer Inc., Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction

  • 1.1 Overview
  • 1.2 Study Goals and Objectives
  • 1.3 Reasons for Doing This Study
  • 1.4 Scope of the Report
  • 1.5 What's New in This Update?
  • 1.6 Methodology and Information Sources
    • 1.6.1 Primary Data and Information Gathering
    • 1.6.2 Secondary Data and Information Gathering
    • 1.6.3 Market Share Analysis and Market Forecast Prediction
  • 1.7 Geographic Breakdown
  • 1.8 Analyst's Credentials
  • 1.9 BCC Custom Research
  • 1.10 Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Cardiovascular Disease and Its Associated Burden

  • 3.1 Overview of Cardiovascular Disease
    • 3.1.1 Coronary Artery Disease
  • 3.2 Atherosclerosis
  • 3.3 Angina (Angina Pectoris)
  • 3.4 Acute Myocardial Infarction (AMI)
  • 3.5 Disease Management
  • 3.6 Medical Management
  • 3.7 Lifestyle Changes
  • 3.8 Diet Modification
  • 3.9 Smoking Cessation
  • 3.10 Pharmaceuticals
  • 3.11 Anticoagulants and Antiplatelet Drugs
  • 3.12 Lipid-Lowering Drugs
  • 3.13 Anti-hypertensive Drugs
  • 3.14 Nitroglycerin Preparations
  • 3.15 Surgical Intervention
    • 3.15.1 Coronary Artery Bypass Graft Surgery
    • 3.15.2 Transmyocardial Revascularization
    • 3.15.3 Percutaneous Coronary Interventions
  • 3.16 Global Burden of Cardiovascular Disease
    • 3.16.1 CVD and Its Associated Burden, 2030
    • 3.16.2 Economic Burden of CVD

Chapter 4 Introduction to Cardiac Biomarkers

  • 4.1 Types of Biomarkers
    • 4.1.1 Antecedent Biomarker Tests
    • 4.1.2 Screening Biomarker Tests
    • 4.1.3 Diagnostic Biomarker Tests
    • 4.1.4 Staging Biomarkers
    • 4.1.5 Prognostic Biomarker Tests
  • 4.2 Role of Biomarkers in the Prevention, Assessment and Management of Heart Failure
    • 4.2.1 Myocardial Stress/Injury
    • 4.2.2 Neurohormonal Activation
    • 4.2.3 Remodeling
    • 4.2.4 Comorbidities
    • 4.2.5 Other Biomarkers of Cardiac Activity
    • 4.2.6 Role of Biomarkers in Heart Failure Clinical Trials
  • 4.3 Biomarker Discovery and Validation
    • 4.3.1 Biomarker Candidate Screening
    • 4.3.2 Biomarker Candidate Validation
  • 4.4 Omic Technologies for Biomarker Discovery
    • 4.4.1 Genomics
    • 4.4.2 Proteomics
    • 4.4.3 Metabolomics
    • 4.4.4 Lipidomics
  • 4.5 Considerations When Developing a Cardiac Biomarker
  • 4.6 Defining Abnormal Biomarker Values
    • 4.6.1 Reference Limits
    • 4.6.2 Discrimination Limits
    • 4.6.3 Threshold Defining Risk
  • 4.7 Receiver Operating Characteristic Curve Analysis of Biomarker Accuracy

Chapter 5 Review of Key Individual Cardiac Biomarkers

  • 5.1 Gold Standard of Cardiac Biomarkers
  • 5.2 Troponin Complex
    • 5.2.1 Troponin C
    • 5.2.2 Troponin T
    • 5.2.3 Troponin I
    • 5.2.4 Troponin as the Preferred Biomarker
    • 5.2.5 High Sensitivity Troponin Assays
    • 5.2.6 Emergence of Point-of-Care Troponin Testing
  • 5.3 Pro-BNP and/or NT-proBNP
  • 5.4 Creatine Kinase Test
  • 5.5 Myoglobin (Mb)
  • 5.6 C-Reactive Protein
  • 5.7 Other Key Cardiac Biomarkers
    • 5.7.1 Copeptin
    • 5.7.2 D-dimer
    • 5.7.3 Galectin-3
    • 5.7.4 Fatty Acid Binding Proteins
    • 5.7.5 ST2
  • 5.8 Emerging Cardiac Biomarkers
    • 5.8.1 Choline
    • 5.8.2 Ischemia-Modified Albumin
    • 5.8.3 Myeloperoxidase
    • 5.8.4 S100-beta
  • 5.9 Recent Technological Advances and Key Developments in Cardiac Biomarker Measurement
    • 5.9.1 Drivers
    • 5.9.2 Barriers
    • 5.9.3 Validation Hurdles
    • 5.9.4 Notable Technological Advancements

Chapter 6 Global Market for Cardiac Biomarkers

  • 6.1 Introduction
  • 6.2 Global Market for Cardiac Biomarkers, by Type of Biomarker
    • 6.2.1 Regional Overview
  • 6.3 North American Market
    • 6.3.1 Selected Market Drivers
    • 6.3.2 Selected Market Restraints
    • 6.3.3 North American Market, by Country
  • 6.4 European Market
    • 6.4.1 Selected Market Drivers
    • 6.4.2 Selected Market Restraints
    • 6.4.3 European Market, by Country
  • 6.5 Asia-Pacific Market
    • 6.5.1 Selected Market Drivers
    • 6.5.2 Selected Market Restraints
    • 6.5.3 Asia-Pacific Market, by Country
  • 6.6 Rest of World Market
    • 6.6.1 Selected Market Drivers
    • 6.6.2 Selected Market Restraints

Chapter 7 Impact of the COVID-19 Pandemic

  • 7.1 Overview
  • 7.2 Impact of COVID-19 on the Market for Cardiac Biomarkers

Chapter 8 Regulatory and Legislative Requirements for Cardiac Biomarkers

  • 8.1 North America
    • 8.1.1 U.S.
    • 8.1.2 Recent Developments
    • 8.1.3 Canada
  • 8.2 Europe
    • 8.2.1 (General) Medical Device Directive, MDD (93/42/EEC)
    • 8.2.2 Active Implantable Medical Device Directive, AIMDD (90/383/EEC)
    • 8.2.3 In Vitro Diagnostic Medical Device Directive, IVDMDD (98/79/EC)
    • 8.2.4 Proposed Changes to the Medical Device Directive, MDD (93/42/EEC)
    • 8.2.5 Notified Bodies
    • 8.2.6 German Reimbursement Structure and Schedules for Diagnostic Procedures
    • 8.2.7 French Reimbursement Structure and Schedules for Diagnostic Procedures
    • 8.2.8 Italian Reimbursement Structure and Schedules for Diagnostic Procedures
  • 8.3 Japan
    • 8.3.1 Marketing Authorization System
  • 8.4 China
    • 8.4.1 Overview of the Healthcare System
    • 8.4.2 Healthcare Reforms
    • 8.4.3 Healthcare Institutions
  • 8.5 India
    • 8.5.1 Overview of the Healthcare System
    • 8.5.2 Hospital Resources
    • 8.5.3 Population Statistics
  • 8.6 South Korea
  • 8.7 Brazil
    • 8.7.1 Background
    • 8.7.2 Regulatory and Legislative Requirements
    • 8.7.3 Market Entry and Reimbursement of Medical Devices
  • 8.8 Argentina
    • 8.8.1 Background
  • 8.9 Mexico
    • 8.9.1 Legislation and Regulations Governing Medical Devices in Mexico
    • 8.9.2 Health Insurance Structure

Chapter 9 Patent Review and New Developments in Cardiac Biomarkers

  • 9.1 Introduction
  • 9.2 Cardiac Biomarker Patents, by Region and Country

Chapter 10 Competitive Landscape

  • 10.1 Company Market Share Analysis
  • 10.2 Recent News

Chapter 11 Company Profiles

  • ABBOTT LABORATORIES
  • ACS BIOMARKER BV
  • BECKMAN COULTER (SUBSIDIARY OF DANAHER CORP.)
  • BG MEDICINE INC.
  • BIOMERIEUX S.A.
  • BIO-RAD LABORATORIES, INC.
  • CARDIOGENICS
  • CREATIVE DIAGNOSTICS
  • CRITICAL DIAGNOSTICS
  • LIFE DIAGNOSTICS INC.
  • LIFESIGN
  • LSI MEDIENCE CORP.
  • MERIDIAN LIFE SCIENCE INC.
  • METANOMICS HEALTH GMBH
  • ORTHO-CLINICAL DIAGNOSTICS INC.
  • PERKINELMER INC.
  • PTS DIAGNOSTICS
  • QUIDEL CORP.
  • RADIOMETER MEDICAL APS
  • RANDOX LABORATORIES LTD.
  • RESPONSE BIOMEDICAL CORP.
  • ROCHE DIAGNOSTICS
  • SANYO CHEMICAL INDUSTRIES LTD.
  • SIEMENS AG
  • SINGULEX INC.
  • SPECTRAL MEDICAL INC.
  • THERMO FISHER SCIENTIFIC, INC.
  • TOSOH BIOSCIENCE INC.
  • TRINITY BIOTECH PLC

Chapter 12 Appendix A: Company Addresses and Contact Details

  • 12.1 Company Addresses and Contact Details

Chapter 13 Appendix B: Government Regulatory Agencies and Professional Organizations

  • 13.1 Government Regulatory Agencies and Professional Organizations

Chapter 14 Appendix C: Commonly Used Acronyms Associated with Cardiac Biomarkers

List of Tables

  • Summary Table B : Global Market Shares of Cardiac Biomarkers, by Region, 2021
  • Summary Table A : Global Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 1 : Standard Angina Pectoris Classification
  • Table 2 : Top 20 Leading Causes of Deaths Globally, 2019
  • Table 3 : Estimated Deaths Due to Noncommunicable Diseases, by Gender and Disease, 2019
  • Table 4 : Estimated Deaths Due to Cardiovascular Disease, by Gender and Disease, 2019
  • Table 5 : Global Health Estimates, by Gender and WHO Region, 2019
  • Table 6 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age, 2019
  • Table 7 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2019
  • Table 8 : Estimated Deaths Due to Cardiovascular Disease, by Gender and Disease, 2030
  • Table 9 : Estimated Deaths Due to Cardiovascular Disease, by Gender and WHO Region, 2030
  • Table 10 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2030
  • Table 11 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age, 2030
  • Table 12 : Economic Burden of NCDs in India, 2012-2030
  • Table 13 : Summary of Heart Failure Biomarkers
  • Table 14 : Cardiac Biomarkers of Myocyte Stretch
  • Table 15 : Cardiac Biomarkers of Myocyte Injury
  • Table 16 : Cardiac Biomarkers of Oxidative Stress
  • Table 17 : Cardiac Biomarkers of Neurohormonal Activation
  • Table 18 : Prognostic and Diagnostic Values and Analytical Performance of Inflammatory Markers in Coronary Artery Disease
  • Table 19 : Cardiac Biomarkers of Inflammation and Atherogenesis
  • Table 20 : Cardiac Biomarkers of Renal Dysfunction
  • Table 21 : Soluble Cell Adhesion Molecules
  • Table 22 : Cardiac Biomarkers of Thrombosis
  • Table 23 : Cardiac Biomarkers of Metabolic/Lipid Dysregulation
  • Table 24 : Cardiac Biomarkers of Brain Damage
  • Table 25 : Techniques Available for Biomarker Development
  • Table 26 : Desirable Features of Cardiac Biomarkers
  • Table 27 : Common Cardiac Biomarkers
  • Table 28 : Contemporary Cardiac Troponin I and T Assay Analytical Characteristics as Designated by the Manufacturer
  • Table 29 : High Sensitivity* Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer
  • Table 30 : Point-of-Care Cardiac Troponin I and T Assay Analytical Characteristics Designated by Manufacturer
  • Table 31 : BNP, NT-proBNP and MR-proANP Assays: Analytical Characteristics Designated by Manufacturer
  • Table 32 : Profile of Biomarker Myoglobin
  • Table 33 : Profile of Biomarker ST2
  • Table 34 : Global Market for Cardiac Biomarkers, Through 2027
  • Table 35 : Global Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 36 : Global Market Shares of Cardiac Biomarkers, by Type of Biomarker, 2021
  • Table 37 : Global Market Shares of Cardiac Biomarkers, by Region, 2021
  • Table 38 : Global Market for Cardiac Biomarkers, by Region, 2027
  • Table 39 : Global Market for Cardiac Biomarkers, by Instrument Category, Through 2027
  • Table 40 : North American Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 41 : North American Market for Cardiac Biomarkers, by Instrument Category, Through 2027
  • Table 42 : Number of Persons Aged 65 Years or Over, Globally, by Region, 2019 and 2050
  • Table 43 : Rough Projections of CVD Prevalence in the U.S., 2010-2030
  • Table 44 : North American Market Shares of Cardiac Biomarkers , by Country, 2021
  • Table 45 : U.S. Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 46 : Canadian Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 47 : European Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 48 : European Market for Cardiac Biomarkers, by Instrument Category, Through 2027
  • Table 49 : European Market Shares of Cardiac Biomarkers, by Country, 2021
  • Table 50 : French Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 51 : German Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 52 : Italian Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 53 : Spanish Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 54 : U.K. Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 55 : Rest of the European Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 56 : Asia-Pacific Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 57 : Asia-Pacific Market for Cardiac Biomarkers, by Instrument Category, Through 2027
  • Table 58 : Asia-Pacific Market Shares of Cardiac Biomarkers, by Country, 2021
  • Table 59 : Japanese Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 60 : Chinese Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 61 : Indian Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 62 : South Korean Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 63 : Australian Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 64 : Rest of Asia-Pacific Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 65 : RoW Market for Cardiac Biomarkers, by Type of Biomarker, Through 2027
  • Table 66 : RoW Market for Cardiac Biomarkers, by Instrument Category, Through 2027
  • Table 67 : ICD-9 and ICD 10 CM Diagnosis Codes Commonly Used to Report Cardiac Conditions
  • Table 68 : Clinical Diagnostic Laboratory Fee Schedule, 2021
  • Table 69 : Comparison of Pharmaceutical Affair Law and Japanese Medical Device Nomenclature and Related Codes with the EU MDD
  • Table 70 : Number of Different Types of Medical Institutions and Beds Provided in Each Institution Type in China, 2018-2019
  • Table 71 : Total Number of Hospitals, by Ranking in China, 2019
  • Table 72 : Overview of Healthcare in India
  • Table 73 : Recent Asia-Pacific Patent Publications Related to Cardiac Biomarkers
  • Table 74 : Recent Chinese Patent Publications Related to Cardiac Biomarkers
  • Table 75 : Recent European Patent Publications Related to Cardiac Biomarkers
  • Table 76 : Recent U.S. Patent Publications Related to Cardiac Biomarkers
  • Table 77 : Recent Canadian Patent Publications Related to Cardiac Biomarkers
  • Table 78 : Recent Global Patent Publications Related to Cardiac Biomarkers
  • Table 79 : Abbott Laboratories: Annual Revenue, by Business Segment, 2019-2021
  • Table 80 : Abbott Laboratories: Diagnostics Revenue, by Segment, 2019-2021
  • Table 81 : Danaher Corp.: Revenue, by Business Segment, 2019-2021
  • Table 82 : bioMerieux S.A.: Recent Financial Performance, FY 2019-FY 2021
  • Table 83 : Bio-Rad Laboratories, Inc.: Annual Revenue, by Business Segment, 2019-2021
  • Table 84 : Meridian Life Science Inc.: Annual Revenue, by Business Segment, 2019-2021
  • Table 85 : Meridian Life Science Inc.: Revenue, by Life Sciences Segment, 2019-2021
  • Table 86 : PerkinElmer Inc.: Recent Financial Performance, FY 2019-FY 2021
  • Table 87 : PerkinElmer Inc.: Annual Revenue, by Business Segment, FY 2019-FY 2021
  • Table 88 : Quidel Corp.: Recent Financial Performance, FY 2019-FY 2021
  • Table 89 : Roche Group: Annual Revenue, by Business Segment, 2019-2021
  • Table 90 : Roche Group: Annual Revenue, by Diagnostics Segment, 2019-2021
  • Table 91 : Siemens Healthineers: Annual Revenue, by Business Segment, 2019-2021
  • Table 92 : Siemens Healthineers' Cardiovascular Assay Menu
  • Table 93 : Thermo Fisher Scientific, Inc.: Annual Revenue, by Business Segment, 2019-2021
  • Table 94 : Thermo Fisher Scientific, Inc.: Results of Operations, by Region, 2019-2021
  • Table 95 : Tosoh Biosciences Inc.: Recent Financial Performance, FY 2019-FY 2021
  • Table 96 : Tosoh Biosciences Inc.: Cardiac Biomarkers Product Portfolio
  • Table 97 : Trinity Biotech Plc.: Annual Revenue, by Business Segment, 2019-2021
  • Table 98 : Company Addresses and Contact Details
  • Table 99 : Government Regulatory Agencies and Professional Organizations Associated with Cardiac Biomarkers
  • Table 100 : Commonly Used Acronyms Associated with Cardiac Biomarkers

List of Figures

  • Summary Figure A : Global Market Shares of Cardiac Biomarkers, by Type of Biomarker, 2021
  • Summary Figure B : Global Market Shares of Cardiac Biomarkers, by Region, 2021
  • Figure 1 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age Group, 2019
  • Figure 2 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, 2019
  • Figure 3 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2019
  • Figure 4 : Global Distribution of Female Deaths Caused, by Cardiovascular Disease, 2019
  • Figure 5 : Global Distribution of Male Deaths Caused by Cardiovascular Disease, by Age, 2030
  • Figure 6 : Global Distribution of Male Deaths Caused, by Cardiovascular Disease, 2030
  • Figure 7 : Global Distribution of Female Deaths Caused by Cardiovascular Disease, by Age Group, 2030
  • Figure 8 : Global Distribution of Female Deaths Caused, by Cardiovascular Disease, 2030
  • Figure 9 : Projected Total Costs of Cardiovascular Disease in the U.S., 2015-2030
  • Figure 10 : Classes of Biomarkers Contributing to the HF Biomarker Profile
  • Figure 11 : Possible Roles of C-Reactive Protein in the Pathogenesis of Metabolic Syndrome and Cardiovascular Disorders
  • Figure 12 : Biomarker Use in Heart Failure Trials
  • Figure 13 : Approaches to Defining Abnormal Biomarker Values
  • Figure 14 : Receiver Operating Characteristic Curve in Different Cardiac Biomarkers
  • Figure 15 : Interpreting Elevated Levels of Cardiac Troponin
  • Figure 16 : Comparison of 19 Cardiac Troponin Assays
  • Figure 17 : Schematic Diagram of the Synthesis of NT-proBNP and BNP from the Pre-proBNP Protein by Cardiomyocytes
  • Figure 18 : Interpretation of NT-proBNP Values as a Predictor of Heart Failure
  • Figure 19 : Global Market Shares of Cardiac Biomarkers, by Type of Biomarker, 2021
  • Figure 20 : Global Market Shares of Cardiac Biomarkers, by Region, 2021
  • Figure 21 : North American Market for Cardiac Biomarkers, by Type of Biomarker, 2021
  • Figure 22 : North American Market Shares of Cardiac Biomarkers Market, by Country, 2021
  • Figure 23 : U.S. Market for Cardiac Biomarkers, by Type of Biomarker, 2021
  • Figure 24 : European Market for Cardiac Biomarkers, by Type of Biomarker, 2021
  • Figure 25 : European Market Shares of Cardiac Biomarkers, by Country, 2021
  • Figure 26 : Asia-Pacific Market for Cardiac Biomarkers, by Type of Biomarker, 2021
  • Figure 27 : Asia-Pacific Market Shares of Cardiac Biomarkers, by Country, 2021
  • Figure 28 : RoW Market for Cardiac Biomarkers, by Type of Biomarker, 2021
  • Figure 29 : U.S. General Population with Private Health Insurance Coverage, 2013-2021
  • Figure 30 : Illustration of Medicare Payment Process in the U.S.
  • Figure 31 : French Pricing and Reimbursement Process for Medical Devices
  • Figure 32 : Market Access Pathway for Inpatient Medical Devices in Italy
  • Figure 33 : Market Access Pathway for Outpatient Medical Devices in Italy
  • Figure 34 : The Chinese Healthcare System
  • Figure 35 : Global Market Shares of Cardiac Biomarkers, by Manufacturer, 2021
  • Figure 36 : bioMerieux S.A.: Sales Share, by Application, 2021
  • Figure 37 : Quidel Corp.: Revenue Share, by Product Segment, FY 2021